Krill Extracts for Treatment of Cardiovascular Diseases

• US 20110305771A1
• Filed: 08/24/2011
• Published: 12/15/2011
• Est. Priority Date: 06/18/2001
• Status: Abandoned Application

• Current Assignee: Aker BioMarine Antarctic AS (Aker BioMarine ASA)
• Original Assignee: Neptune Technologies & Bioressources Incorporated (Quebec)
• Inventors: Sampalis, Tina
• Application Number:
  US13/216,694
• Publication Number:
  US 20110305771A1
• Time in Patent Office: Days
• US Class Current: 424/522
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/015 carbocyclic
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/232 having three or more double bonds, e.g. etretinate
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/683 Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 31/688 both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 35/612 Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/48 Preparations in capsules, e.g. of gelatin, of chocolate A61K9/0004 takes precedence; bite capsules A61K9/0056
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 : for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/08 : for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 5/24 : of the sex hormones
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/06 : Antiarrhythmics
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives

Abstract

The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases.

Claims

1. A method of decreasing cholesterol in a patient, said method comprising administering to a patient in need thereof an effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

3. The method of claim 2, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

4. The method of claim 3, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

5. The method of claim 4, wherein said administering is effected orally.

6. The method of claim 4, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

7. The method of claim 6, wherein said quantity is 4.8 grams.

8. A method of inhibiting platelet adhesion and plaque formation in arteries of a patient comprising administering to a patient in need thereof an effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

9. The method of claim 8, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

10. The method of claim 9, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

11. The method of claim 10, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

12. The method of claim 11, wherein said administering is effected orally.

13. The method of claim 11, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

14. The method of claim 13, wherein said quantity is 4.8 grams.

15. A method for preventing hypertension in a patient comprising a administering to a patient in need thereof an effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

16. The method of claim 15, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

17. The method of claim 16, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

18. The method of claim 17, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

19. The method of claim 18, wherein said administering is effected orally.

20. The method of claim 18, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

21. The method of claim 20, wherein said quantity is 4.8 grams.

22. A method for symptomatic controlling or treating arthritis in a patient comprising administering to a patient in need thereof a therapeutically effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

23. The method of claim 22, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

24. The composition of claim 23, wherein said arthritis is selected from the group consisting of rheumatoid arthritis and osteoarthritis.

25. The method of claim 24, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

26. The method of claim 25, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

27. The method of claim 26, wherein said administering is effected orally.

28. The method of claim 26, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

29. The method of claim 28, wherein said quantity is 4.8 grams.

30. A method for prevention of skin cancer in a patient comprising administering to a patient in need thereof a prophylactic effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

31. The method of claim 30, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

32. The method of claim 31, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

33. The method of claim 32, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

34. The method of claim 33, wherein said administering is effected orally.

35. The method of claim 33, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

36. The method of claim 35, wherein said quantity is 4.8 grams.

37. A method for enhancing transdermal transportation for dermatological applications in a patient comprising administering to a patient in need thereof an enhancing effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

38. The method of claim 37, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

39. The method of claim 38, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

40. The method of claim 39, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

41. The method of claim 40, wherein said administering is effected orally and/or topically.

42. The method of claim 40, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

43. The method of claim 42, wherein said quantity is 4.8 grams.

44. A method for reducing premenstrual syndrome'"'"'s symptoms in a patient comprising administering to a patient in need thereof an enhancing effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

45. The method of claim 44, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

46. The method of claim 45, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

47. The method of claim 46, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

48. The method of claim 47, wherein said administering is effected orally.

49. The method of claim 47, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

50. The method of claim 49, wherein said quantity is 4.8 grams.

51. A method for controlling blood glucose level in a patient comprising administering to a patient in need thereof an enhancing effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.

52. The method of claim 51, wherein said krill and/or marine oil is obtained from a process comprising the steps of:

a) placing krill and/or marine material in a ketone solvent, preferably acetone to achieve extraction of the soluble lipid fraction from said marine and/or aquatic animal material;

b) separating the liquid and solid contents;

c) recovering a first lipid rich fraction from the liquid contents by evaporation of the solvent present in the liquid contents;

d) placing said solid contents in an organic solvent selected from the group of solvents consisting of alcohol, preferably ethanol, isopropanol or t-butanol and esters of acetic acid, preferably ethyl acetate to achieve extraction of the remaining soluble lipid fraction from said marine and/or aquatic animal material;

e) separating the liquid and solid contents;

f) recovering a second lipid rich fraction by evaporation of the solvent from the liquid contents; and

g) recovering the solid contents.

53. The method of claim 52, wherein said krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, α

-tocopherol, Astaxanthin, and flavonoid.

54. The method of claim 53, wherein said krill and/or marine oil further comprises at least one of the group consisting of Linoleic acid, Alpha-linoleic acid, arachidonic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid, cholesterol, triglycerides, monoglycerides, all-trans retinol, canthaxanthin, β

-carotene, zinc, selenium, nervonic acid, sodium, potassium and calcium.

55. The method of claim 54, wherein said administering is effected orally.

56. The method of claim 54, wherein said krill and/or marine extract is administered in a quantity in a range of 1 to 4.8 grams per day.

57. The method of claim 56, wherein said quantity is 4.8 grams.